Top Markets
#1 Helium Helium +58.78%
#2 Seeker Seeker +45.10%
#3 Pons Pons +37.43%
#4 Tensor Tensor +27.31%
#5 UnifAI Network UnifAI Network +26.57%
#6 TENDIES TENDIES +21.30%
#7 DAPPOS DAPPOS +17.14%
#8 Zylo Ecosystem Zylo Ecosystem +16.61%
#9 Bounce Bounce +16.46%
#10 LAB LAB +16.14%
Coin of the day
Helium Helium
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Philogen S.p.A. Philogen S.p.A.

Philogen S.p.A.

PHIL
Classifica tra le azioni #10685
Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic... Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.
Prezzo delle azioni
$27.76
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$801.60M
Variazione (1 giorno)
0.21%
Variazione (1 anno)
0.65%
Paese
IT
Scambia Philogen S.p.A. (PHIL)

Categoria

Healthcare
Storico del prezzo dell'azione per Philogen S.p.A. (PHIL)
Prezzo di chiusura più alto: $28.10 il 2026-08-01

Prezzo di chiusura più basso: $17.28 il 2023-06-01
Storico del prezzo dell'azione di Philogen S.p.A. dal 2023 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -1.23%
2025 37.47%
2024 0.27%
2023 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.53 -12.70%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $759.27 7.20%
CH